Clinical Trial Update: Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a radiolabeled antibody with Yttrium-90 for advanced renal cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Kidney Neoplasm
• Renal Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Chimeric G250

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Renal Cell Carcinoma, Kidney Neoplasm | Phase 1 | Status: COMPLETED | Results posted: 2018-11-28